Benefit of tolcapone in patients with early Parkinson's disease

被引：0
|
作者：
Suchowersky, O
Martin, WRW
Bailey, P
Argatoff, P
Roberts, T
Hodder, J
Bailey, S
Brant, R
机构：
来源：
NEUROLOGY | 1996年 / 46卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：4001 / 4001
页数：1
相关论文
共 50 条
  • [41] Sleep benefit in Parkinson's disease
    Montagna, P
    Lugaresi, E
    [J]. MOVEMENT DISORDERS, 1998, 13 (04) : 751 - 752
  • [42] 'Sleep benefit' in Parkinson's disease
    Factor, SA
    Weiner, WJ
    [J]. NEUROLOGY, 1998, 50 (05) : 1514 - 1515
  • [43] Sleep benefit in Parkinson's disease
    Merello, M
    Hughes, A
    Colosimo, C
    Hoffman, M
    Starkstein, S
    Leiguarda, R
    [J]. MOVEMENT DISORDERS, 1997, 12 (04) : 506 - 508
  • [44] Sleep benefit in Parkinson's disease
    Bateman, DE
    Levett, K
    Marsden, CD
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 67 (03): : 384 - 385
  • [45] Sleep benefit in Parkinson's disease
    van Gilst, M.
    [J]. JOURNAL OF SLEEP RESEARCH, 2014, 23 : 53 - 53
  • [46] Sleep benefit in Parkinson's disease
    Högl, B
    Gershanik, O
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (06): : 798 - 799
  • [47] Effect of tolcapone on peripheral neuropathy in patients with Parkinson's disease treated with levodopa/carbidopa intestinal gel
    Matejicka, P.
    Minar, M.
    Kosutzka, Z.
    Gmitterova, K.
    Valkovic, P.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 906 - 907
  • [48] Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone
    Welsh, MD
    Dorflinger, E
    Chernik, D
    Waters, C
    [J]. MOVEMENT DISORDERS, 2000, 15 (03) : 497 - 502
  • [49] Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson’s disease patients
    Thomas Müller
    Wilfried Kuhn
    [J]. European Journal of Clinical Pharmacology, 2006, 62 : 447 - 450
  • [50] Tolcapone-Related Liver DysfunctionImplications for Use in Parkinson’s Disease Therapy
    Nuno Borges
    [J]. Drug Safety, 2003, 26 : 743 - 747
12345